Analysis of gene copy number alterations by multiplex ligation-dependent probe amplification in columnar cell lesions of the breast

Cellular Oncology

Volumn 37, Issue 2, 2014, Pages 147-154

  Verschuur Maes, Anoek H J ^a   Moelans, Cathy B ^a   De Bruin, Peter C ^b   Van Diest, Paul J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b ST ANTONIUS HOSPITAL   (Netherlands)

Author keywords

Breast; Columnar cell lesions; Flat epithelial atypia; MLPA; Multiplex ligation dependent probe amplification; Oncogenes

Indexed keywords

ARTICLE; BIRC5 GENE; BREAST CARCINOGENESIS; BREAST CARCINOMA; C11ORF30 GENE; CCND1 GENE; CCNE1 GENE; CDH1 GENE; CLINICAL ARTICLE; COLUMNAR CELL LESION; COLUMNAR EPITHELIUM; CONTROLLED STUDY; COPY NUMBER VARIATION; CPD GENE; EGFR GENE; ERBB2 GENE; ESR1 GENE; FGFR1 GENE; GENE AMPLIFICATION; GENE FREQUENCY; HUMAN; HUMAN TISSUE; IKBKB GENE; INTRADUCTAL CARCINOMA; MAPT GENE; MED1 GENE; MTDH GENE; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; ONCOGENE; ONCOGENE MYC; PRECANCER; PRIORITY JOURNAL; TOP2A GENE; TRAF4 GENE; ADULT; AGED; BREAST TUMOR; FEMALE; GENETICS; MIDDLE AGED; MULTIPLEX POLYMERASE CHAIN REACTION; PATHOLOGY; PROCEDURES; TUMOR INVASION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; DNA COPY NUMBER VARIATIONS; FEMALE; GENE AMPLIFICATION; HUMANS; MIDDLE AGED; MULTIPLEX POLYMERASE CHAIN REACTION; NEOPLASM INVASIVENESS; PRECANCEROUS CONDITIONS;

EID: 84899640926     PISSN: 22113428     EISSN: 22113436     Source Type: Journal    
DOI: 10.1007/s13402-014-0170-z     Document Type: Article

References (38)

1. D. Allred, S. Mohsin, S. Fuqua, Histological and biological evolution of human premalignant breast disease. Endocrinol. Relat. Cancer. 8, 47-61 (2001)
2. P. van Diest, Ductal carcinoma in situ in breast carcinogenesis. J. Pathol. 187, 383-384 (1999)
3. S. Lee, D. Medina, A. Tsimelzon, S. Mohsin, S. Mao, Y. Wu, D. Allred, Alterations of gene expression in the development of early hyperplastic precursors of breast cancer. Am. J. Pathol. 171, 252-262 (2007)
4. P. Simpson, T. Gale, J. Reis-Filho, C. Jones, S. Parry, J. Sloane, A. Hanby, S. Pinder, A. Lee, S. Humphreys, I. Ellis, S. Lakhani, Columnar cell lesions of the breast: the missing link in breast cancer progression? A morphological and molecular analysis. Am. J. Surg. Pathol. 29, 734-746 (2005)
5. H. Sinn, Breast cancer precursors: lessons learned from molecular genetics. J. Mol. Med. 87, 113-115 (2009)
6. A. Verschuur-Maes, C. van Gils, M. van den Bosch, P. de Bruin, P. van Diest, Digital mammography: more microcalcifications, more columnar cell lesions without atypia. Mod. Pathol. 24, 1191-1197 (2011)
7. S. Schnitt, A. Vincent-Salomon, Columnar cell lesions of the breast. Adv. Anat. Pathol. 10, 113-124 (2003)
8. F. Tavassoli, P. Devilee, WHO classification tumours of the breast and female genital organs (IARC, Lyon, 2003)
9. L. Feeley, C. Quinn, Columnar cell lesions of the breast. Histopathology 52, 11-19 (2008)
10. A. Verschuur-Maes, C. van Deurzen, E. Monninkhof, P. van Diest, Columnar cell lesions on breast needle biopsies: is surgical excision necessary? A systematic review. Ann. Surg. 255, 259-265 (2012)
11. A. Verschuur-Maes, A. Witkamp, P. de Bruin, E. van der Wall, P. van Diest, Progression risk of columnar cell lesions of the breast diagnosed in core needle biopsies. Int. J. Cancer 129, 2674-2680 (2011)
12. S. Park, H. Kwon, H. Lee, H. Ryu, S. Kim, J. Kim, I. Kim, N. Jung, N. Cho, G. Kang, Promoter CpG island hypermethylation during breast cancer progression. Virchows Arch. 458, 73-84 (2011)
13. A. Verschuur-Maes, P. de Bruin, P. van Diest, Epigenetic progression of columnar cell lesions of the breast to ductal carcinoma in situ and invasive breast cancer. Breast Cancer Res. Treat. 136, 705-715 (2012)
14. S. Aulmann, Z. Elsawaf, R. Penzel, P. Schirmacher, H. Sinn, Invasive tubular carcinoma of the breast frequently is clonally related to flat epithelial atypia and low-grade ductal carcinoma in situ. Am. J. Surg. Pathol. 33, 1646-1653 (2009)
15. D. Dabbs, G. Carter, M. Fudge, Y. Peng, P. Swalsky, S. Finkelstein, Molecular alterations in columnar cell lesions of the breast. Mod. Pathol. 19, 344-349 (2006)
16. F. Moinfar, Y. Man, G. Bratthauer, M. Ratschek, F. Tavassoli, Genetic abnormalities in mammary ductal intraepithelial neoplasia-flat type ("clinging ductal carcinoma in situ"): a simulator of normal mammary epithelium. Cancer 88, 2072-2081 (2000)
17. C. Moelans, R. de Weger, H. Monsuur, R. Vijzelaar, P. van Diest, Molecular profiling of invasive breast cancer by multiplex ligation-dependent probe amplification-based copy number analysis of tumor suppressor and oncogenes. Mod. Pathol. 23, 1029-1039 (2010)
18. P. van Diest, No consent should be needed for using leftover body material for scientific purposes. BMJ. 325, 648-651 (2002)
19. D. Bunyan, D. Eccles, J. Sillibourne, E. Wilkins, N. Thomas, J. Shea-Simonds, P. Duncan, C. Curtis, D. Robinson, J. Harvey, N. Cross, Dosage analysis of cancer predisposition genes by multiplex ligation-dependent probe amplification. Br. J. Cancer 91, 1155-1159 (2004)
20. J. Coffa, M. van de Wiel, B. Diosdado, B. Carvalho, J. Schouten, G. Meijer, MLPAnalyzer: data analysis tool for reliable automated normalization of MLPA fragment data. Cell. Oncol. 30, 323-335 (2008)
21. C. Moelans, R. de Weger, P. van Diest, Multiplex ligation-dependent probe amplification to detect HER2 amplification in breast cancer: new insights in optimal cut-off value. Cell. Oncol. 32, 311-312 (2010)
22. T. Abdel-Fatah, D. Powe, Z. Hodi, J. Reis-Filho, A. Lee, I. Ellis, Morphologic and molecular evolutionary pathways of low nuclear grade invasive breast cancers and their putative precursor lesions: further evidence to support the concept of low nuclear grade breast neoplasia family. Am. J. Surg. Pathol. 32, 513-523 (2008)
23. C. Moelans, R. de Weger, M. van Blokland, C. Ezendam, S. Elshof, M. Tilanus, P. van Diest, HER-2/neu amplification testing in breast cancer by multiplex ligation-dependent probe amplification in comparison with immunohistochemistry and in situ hybridization. Cell. Oncol. 31, 1-10 (2009)
24. C. Moelans, R. de Weger, M. van Blokland, E. van der Wall, P. van Diest, Simultaneous detection of TOP2A and HER2 gene amplification by multiplex ligation-dependent probe amplification in breast cancer. Mod. Pathol. 23, 62-70 (2010)
25. F. Holst, C. Moelans, M. Filipits, C. Singer, R. Simon, P. van Diest, On the evidence for ESR1 amplification in breast cancer. Nat. Rev. Cancer 12, 149 (2012)
26. H. Buerger, R. Simon, K. Schafer, R. Diallo, R. Littmann, C. Poremba, P. van Diest, B. Dockhorn-Dworniczak, W. Bocker, Genetic relation of lobular carcinoma in situ, ductal carcinoma in situ, and associated invasive carcinoma of the breast. Mol. Pathol. 53, 118-121 (2000)
27. D. Gomes, D. Balabram, S. Porto, H. Gobbi, Lobular neoplasia: frequency and association with other breast lesions. Diagn. Pathol. 6, 74 (2011)
28. E. Korsching, J. Packeisen, K. Agelopoulos, M. Eisenacher, R. Voss, J. Isola, P. van Diest, B. Brandt, W. Boecker, H. Buerger, Cytogenetic alterations and cytokeratin expression patterns in breast cancer: integrating a new model of breast differentiation into cytogenetic pathways of breast carcinogenesis. Lab. Invest. 82, 1525-1533 (2002)
29. E. Rakha, A. Green, D. Powe, R. Roylance, I. Ellis, Chromosome 16 tumor-suppressor genes in breast cancer. Genes, Chromosomes Cancer 45, 527-535 (2006)
30. D. Zou, H. Yoon, D. Perez, R. Weeks, P. Guilford, B. Humar, Epigenetic silencing in non-neoplastic epithelia identifies E-cadherin (CDH1) as a target for chemoprevention of lobular neoplasia. J. Pathol. 218, 265-272 (2009)
31. C. Moelans, R. de Weger, H. Monsuur, A. Maes, P. van Diest, Molecular differences between ductal carcinoma in situ and adjacent invasive breast carcinoma: a multiplex ligation-dependent probe amplification study. Anal. Cell. Pathol. (Amst.) 33, 165-173 (2010)
32. C. Moelans, R. de Weger, P. van Diest, Absence of chromosome 17 polysomy in breast cancer: analysis by CEP17 chromogenic in situ hybridization and multiplex ligation-dependent probe amplification. Breast Cancer Res. Treat. 120, 1-7 (2010)
33. T. Kirkegaard, K. Nielsen, L. Jensen, F. Campbell, S. Muller, S. Tovey, S. Brown, T. Cooke, J. Bartlett, Genetic alterations of CCND1 and EMSY in breast cancers. Histopathology 52, 698-705 (2008)
34. M. Mano, D. Rosa, A. De, G. Ismael, V. Durbecq, The 17q12-q21 amplicon: Her2 and topoisomerase-IIalpha and their importance to the biology of solid tumours. Cancer Treat. Rev. 33, 64-77 (2007)
35. M. Tanner, J. Isola, T. Wiklund, B. Erikstein, P. Kellokumpu-Lehtinen, P. Malmstrom, N. Wilking, J. Nilsson, J. Bergh, Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401. J. Clin. Oncol. 24, 2428-2436 (2006)
36. C. Moelans, P. van Diest, Re: How do you tell whether a breast cancer is HER2 positive? Ongoing studies keep debate in high gear. J. Natl. Cancer Inst. 103, 698-699 (2011)
37. K. Agelopoulos, B. Greve, H. Schmidt, H. Pospisil, S. Kurtz, K. Bartkowiak, A. Andreas, M. Wieczorek, E. Korsching, H. Buerger, B. Brandt, Selective regain of egfr gene copies in CD44+/CD24-/low breast cancer cellular model MDA-MB-468. BMC Cancer. 10, 78 (2010)
38. C. Moelans, A. Verschuur-Maes, P. van Diest, Frequent promoter hypermethylation of BRCA2, CDH13, MSH6, PAX5, PAX6 and WT1 in ductal carcinoma in situ and invasive breast cancer. J. Pathol. 225, 222-231 (2011)